Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €0.18 EUR
Change Today 0.00 / 0.00%
Volume 292.4K
BTH1V On Other Exchanges
Symbol
Exchange
Helsinki
Berlin
OTC US
As of 11:29 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

biotie therapies oyj (BTH1V) Snapshot

Open
€0.18
Previous Close
€0.18
Day High
€0.18
Day Low
€0.18
52 Week High
05/27/14 - €0.25
52 Week Low
03/31/15 - €0.18
Market Cap
83.4M
Average Volume 10 Days
294.1K
EPS TTM
€-0.07
Shares Outstanding
456.0M
EX-Date
03/30/06
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTIE THERAPIES OYJ (BTH1V)

Related News

No related news articles were found.

biotie therapies oyj (BTH1V) Related Businessweek News

No Related Businessweek News Found

biotie therapies oyj (BTH1V) Details

Biotie Therapies Corp. operates as a drug development company. It focuses on the development of drugs for neurodegenerative and psychiatric disorders. Its products include Selincro (nalmefene), a dual-acting opioid system modulator that reduces alcohol consumption in alcohol dependent individuals; Tozadenant (SYN115), an oral, potent and selective adenosine A2a receptor antagonist for the treatment of Parkinson’s disease that is in Phase III development; NRL-1 a proprietary intranasal formulation of diazepam for the treatment of epilepsy; Nepicastat (SYN117) an orally administered inhibitor for the treatment for cocaine dependence, which is in Phase II trial. The company’s products also comprise BTT-1023 a monoclonal antibody for treatment of inflammatory diseases focusing on conducting Phase 2 clinical trial; and SYN120 an oral, potent, dual antagonist of the 5-HT6 and 5HT2a receptors that has completed single and multiple ascending dose Phase I clinical studies and a Phase I positron emission tomography imaging study to determine therapeutic dose. The company has strategic collaboration with UCB Pharma S.A. Biotie Therapies Corp. is based in Turku, Finland.

38 Employees
Last Reported Date: 03/9/15

biotie therapies oyj (BTH1V) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biotie therapies oyj (BTH1V) Key Developments

Biotie Therapies Corp Announces Start of Patient Enrolment into Phase 2A Clinical Study with BTT1023 in Primary Sclerosing Cholangitis

Biotie Therapies Corp. announced the start of patient enrolment into the phase 2a clinical study evaluating BTT1023, Biotie's fully human monoclonal antibody targeting Vascular Adhesion Protein-1, in primary sclerosing cholangitis (PSC). PSC is a progressive immune mediated biliary disease characterized by bile duct inflammation and fibrosis, and accompanying hepatic fibrosis, that frequently results in the need for liver transplantation. The study is being funded through the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership. The BUTEO study (BTT1023, a human monoclonal antibody targeting vascular adhesion protein (VAP-1), in the treatment of patients with primary sclerosing cholangitis) is an investigator-sponsored open label, single arm, multi-centre study that will evaluate efficacy, safety and pharmacokinetic properties of BTT1023 in 41 patients with PSC. Patients will receive BTT1023 via intravenous infusion every two weeks over an 11 week treatment period. The primary efficacy endpoint is a reduction of elevated levels of alkaline phosphatase, a blood biomarker of bile duct inflammation; secondary endpoints include various measures of liver injury and fibrosis. The two-stage study design includes a pre-planned futility analysis. Based on current estimates, it is expected that the requisite number of patients will have been treated by the end of 2016 to enable the futility analysis to be completed.

Biotie Therapies Corp. Reports Consolidated and Parent Earnings Results for the Full Year Ended December 31, 2014

Biotie Therapies Corp. reported consolidated and parent earnings results for the full year ended December 31, 2014. For the year, on consolidated basis, the company reported operating loss was EUR 36,090,000 compared to income of EUR 1,499,000 a year ago. Income loss before taxes was EUR 35,165,000 compared to income of EUR 3,651,000 a year ago. Net loss was EUR 35,165,000 compared to income of EUR 5,846,000 a year ago. Investments in property, plant and equipment was EUR 146,000 compared to EUR 329,000 a year ago. Investments in intangible assets were EUR 50,000 compared to EUR 52,000 a year ago. Return on equity was negative 52.9% compared to 4.7% a year ago. For the year, on parent basis, revenue was EUR 7,278,000 compared to EUR 4,485,000 a year ago. Operating loss was EUR 278,000 compared to EUR 3,010,000 a year ago. Profit before extraordinary items, appropriations and taxes were EUR 5,090,000 compared to loss of EUR 509,000 a year ago. Net income was EUR 5,090,000 compared to loss of EUR 509,000 a year ago. Cash flow used in operating activities was EUR 229,000 compared to EUR 4,039,000 a year ago. Capital expenditure was EUR 39,000 compared to EUR 83,000 a year ago.

Biotie Therapies Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Biotie Therapies Corp. reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, net loss was EUR 32.4 million compared to net profit of EUR 1.7 million a year ago. Revenues were EUR 1.9 million against EUR 5.8 million a year ago. Cash out flows from operating activities of EUR 4.7 million against EUR 2.8 million a year ago. Loss per share was EUR 0.07. For the year, the company reported revenues were EUR 14.9 million against EUR 27.7 million a year ago. Cash out flow from operating activities was EUR 14.1 million against cash inflows from operating activities of 10.6 million a year ago. Loss per share was EUR 0.08 against earnings per share of EUR 0.01 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BTH1V:FH €0.18 EUR 0.00

BTH1V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BTH1V.
View Industry Companies
 

Industry Analysis

BTH1V

Industry Average

Valuation BTH1V Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.1x
Price/Book 1.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTIE THERAPIES OYJ, please visit www.biotie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.